このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Alpine Immune Sciences, Inc. 競合他社
価格と性能
| Historical stock prices | |
|---|---|
| Current Share Price | US$64.97 |
| 52 Week High | US$65.00 |
| 52 Week Low | US$8.33 |
| Beta | 0.97 |
| 1 Month Change | 0.65% |
| 3 Month Change | 113.79% |
| 1 Year Change | 518.17% |
| 3 Year Change | 520.53% |
| 5 Year Change | 1,270.68% |
| Change since IPO | 580.31% |
最新ニュース
Recent updates
Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement
Apr 11Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts
Mar 21
Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation
Mar 20Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug
Mar 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up
Feb 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up
Dec 19We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth
Sep 23Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)
May 11Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?
Dec 12Alpine Immune Sciences drops 13% after hours on $100M stock offering
Sep 20Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt
Aug 09Alpine: Rest Before Rallying Again
Apr 25Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?
Apr 12Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt
Sep 18Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%
Aug 18株主還元
| ALPN | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 0.03% | -2.0% | 1.6% |
| 1Y | 518.2% | 5.4% | 21.5% |
業界別リターン: ALPN過去 1 年間で8.4 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: ALPN過去 1 年間で21.8 % の収益を上げたUS市場を上回りました。
価格変動
| ALPN volatility | |
|---|---|
| ALPN Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: ALPNの株価は過去 3 か月間にわたって変動しています。
時間の経過による変動: ALPNの weekly volatility ( 14% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2007 | 142 | Mitch Gold | www.alpineimmunesciences.com |
Alpine Immune Sciences, Inc. 基礎のまとめ
| ALPN 基礎統計学 | |
|---|---|
| 時価総額 | US$4.46b |
| 収益（TTM） | -US$36.84m |
| 売上高(TTM) | US$56.52m |
78.9x
P/Sレシオ-121.0x
PER（株価収益率ALPN は割高か？
公正価値と評価分析を参照収益と収入
| ALPN 損益計算書（TTM） | |
|---|---|
| 収益 | US$56.52m |
| 売上原価 | US$83.78m |
| 売上総利益 | -US$27.26m |
| その他の費用 | US$9.58m |
| 収益 | -US$36.84m |
直近の収益報告
Mar 31, 2024
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.54 |
| グロス・マージン | -48.23% |
| 純利益率 | -65.17% |
| 有利子負債／自己資本比率 | 0% |
ALPN の長期的なパフォーマンスは？
過去の実績と比較を見る